Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.

Mol Cancer · 2023 · PMC10413520 · PMID 37563723

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The tumor growth curve showed a trend consistent with the longitudinal bioluminescence assay, indicating significant early-stage inhibition of tumor growth in the BsAb-treated group compared with that in the PBS-, PD-1 scFv- and TREM2 scFv-treated groups (Fig. 3 D and Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.